<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03727828</url>
  </required_header>
  <id_info>
    <org_study_id>DRAGON-HF</org_study_id>
    <nct_id>NCT03727828</nct_id>
  </id_info>
  <brief_title>Diagnostic, Risk Stratification and Prognostic Value of Novel Biomarkers in Patients With Heart Failure</brief_title>
  <official_title>Diagnostic, Risk Stratification and Prognostic Value of Novel Biomarkers in Patients With Heart Failure: DRAGON-HF Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai 10th People's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Tongji Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>First Affiliated Hospital, Sun Yat-Sen University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Nanfang Hospital of Southern Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Fuwai Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Yangpu Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shanghai Municipal Hospital of Traditional Chinese Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Huashan Hospital Baoshan Branch</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shanghai Zhongye Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shanghai BaoshanLuodianHospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shanghai Shibei Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Nantong Sixth People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Shanghai 10th People's Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this work is to investigate and then to sequence new biomarkers in the blood
      of patients with heart failure, and study their diagnostic, risk stratification and
      prognostic value.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Blood samples (plasma or serum) for heart failure patients presenting dyspnea or edema and
      with increased NT-proBNP. The objective of this work is to investigate and then to sequence
      new proteins or microRNAs in the blood of these patients for diagnostic, risk stratification
      and prognostic purpose.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 15, 2018</start_date>
  <completion_date type="Anticipated">February 28, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with cardiaovascular death after 5-year follow up</measure>
    <time_frame>5 years</time_frame>
    <description>The cardiovascular mortality after 5-year follow up will be assessed to detect prognostic values of circulating biomarkers</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to decompensated heart failure (HF) requiring in-patient admission or ER visit or IV diuretic therapy in the outpatient realm</measure>
    <time_frame>5 years</time_frame>
    <description>New onset of classic symptoms and signs of destabilized HF, including lower extremity edema, jugular venous distension, bibasilar crackles, orthopnea and paroxysmal nocturnal dyspnea.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Comparison of new biomarker with NT-ProBNP on diagnostic value in patients with heart failure</measure>
    <time_frame>1 year</time_frame>
    <description>Compare the sensitivity and specificity of new biomarker with NT-ProBNP to assess the accuracy of diagnostic value in discriminating heart failure from non-heart failure participants.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in left ventricular ejection fraction</measure>
    <time_frame>5 years</time_frame>
    <description>Assess the change in left ventricular ejection fraction at the end of 5-year follow up.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in left ventricular end-systolic volume</measure>
    <time_frame>5 years</time_frame>
    <description>Assess the change in left ventricular end-systolic volume at the end of 5-year follow up.</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">3000</enrollment>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>Patients with heart failure</arm_group_label>
    <description>Patients with heart failure (HF) who are followed in the hospital or clinic setting, with optimization of medical therapy and blood collection.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>healthy control</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Patients with heart failure</intervention_name>
    <description>Participants will have serial blood collection on medical therapy for heart failure</description>
    <arm_group_label>Patients with heart failure</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Peripheral blood collected at various time points according to the study cohort.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with heart failure.Patients presenting with shortness of breathor edema and with
        increased NT-proBNP.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age &gt; 18 years of age

          2. Symptomatic (NYHA class II-IV) heart failure (as diagnosed by clinician, radiographic
             images, or abnormal natriuretic peptide level)

          3. Hospital admission, Emergency Department visit, or outpatient diuretic escalation of
             therapy for destabilized HF at least once in the 6 months prior to enrollment

        Exclusion Criteria:

          1. Life expectancy &lt;1 year due to causes other than HF such as advanced cancer

          2. Cardiac transplantation or revascularization indicated or expected within 6 months

          3. Severe obstructive or restrictive pulmonary disease, defined as a forced expiratory
             volume in 1 sec &lt;1 L (when diagnosed as standard of care)

          4. Subject unable or unwilling to provide written informed consent

          5. Coronary revascularization (percutaneous coronary intervention or bypass surgery)
             within the previous 3 months

          6. Progressive neurological disease

          7. Pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dachun Xu, Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shanghai 10th People's Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dachun Xu, Ph.D</last_name>
    <phone>0086-18917684045</phone>
    <email>xdc77@tongji.edu.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yuxi Sun, Ph.D</last_name>
    <phone>0086-15216718171</phone>
    <email>sunyuxitj10h@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Shanghai Tenth People's Hospital, Tongji University</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200072</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dachun Xu, MD,PhD</last_name>
      <phone>+86 18917684045</phone>
      <email>xdc77@tongji.edu.cn</email>
    </contact>
    <contact_backup>
      <last_name>Yawei Xu, MD,PhD</last_name>
      <phone>+86 13916698181</phone>
      <email>xuyawei@tongji.edu.cn</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>October 21, 2018</study_first_submitted>
  <study_first_submitted_qc>October 31, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 1, 2018</study_first_posted>
  <last_update_submitted>January 7, 2020</last_update_submitted>
  <last_update_submitted_qc>January 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shanghai 10th People's Hospital</investigator_affiliation>
    <investigator_full_name>Ya-Wei Xu</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>IPD will be available with reasonable request.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

